Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

December 17, 2019

Study Completion Date

December 17, 2019

Conditions
Lymphoma
Interventions
DRUG

atezolizumab

1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).

RADIATION

Low- Dose, Local Radiotherapy

4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memoral Sloan Kettering Basking Ridge, Basking Ridge

07748

Memoral Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER